RxDoctor Payments Data

Shaher Altoumah

Physician Assistant · Loma Linda, CANPI 1962976712

Payments from drug & device makers

$2,537in general payments, 2019–2025

Across 83 payments — averaging $30.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$583
  • Amgen$310
  • AstraZeneca$296
  • Bayer$214
  • Sanofi$195
  • Exact Sciences$147
  • plus $792 from 14 others

What the payments were for

  • Food & beverage$2,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,537 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$13,776
Medicare patients
127
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$83,727
JardianceEmpagliflozin49$52,398
JanuviaSitagliptin Phosphate36$38,159
Diclofenac Sodium28$29,899
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,068
Albuterol Sulfate HfaAlbuterol Sulfate81$3,399
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$2,969
Atorvastatin Calcium295$2,779
Fluticasone Propionate HfaFluticasone Propionate12$2,239
Levothyroxine Sodium96$2,207
Lidocaine17$1,208
Ezetimibe65$952
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$868
Gabapentin53$841
Alcohol PadsAlcohol Antiseptic Pads13$826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$583$83,72790 claims
MerckJanuvia$41$38,15936 claims
GSKTrelegy Ellipta$116$9,06813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →